These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1830302)

  • 1. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.
    Craig WA; Redington J; Ebert SC
    J Antimicrob Chemother; 1991 May; 27 Suppl C():29-40. PubMed ID: 1830302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Amikacin resistance of clinical strains of Enterobacteriaceae and Pseudomonas].
    Moreva TV; Anisimova LA; Erova TE; Boronin AM
    Antibiot Khimioter; 1992 Apr; 37(4):25-8. PubMed ID: 1417311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae.
    Moody JA; Fasching CE; Peterson LR; Gerding DN
    Diagn Microbiol Infect Dis; 1987 Jan; 6(1):59-67. PubMed ID: 3100127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy: a way to limit emergence of resistance?
    Michéa-Hamzehpour M; Pechère JC; Marchou B; Auckenthaler R
    Am J Med; 1986 Jun; 80(6B):138-42. PubMed ID: 3088999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1985 Aug; 16(2):227-34. PubMed ID: 3934125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
    Bhalodi AA; Crandon JL; Williams G; Nicolau DP
    Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of trimethoprim and amikacin against gram-negative bacilli.
    Parsley TL; Provonchee RB; Glicksman C; Zinner SH
    Antimicrob Agents Chemother; 1977 Sep; 12(3):349-52. PubMed ID: 410362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF; Maslow MJ; Leibowitz RE; Pollock AA; Hanna BA; Schaefler S; Simberkoff MS; Rahal JJ
    J Infect Dis; 1985 Feb; 151(2):295-300. PubMed ID: 3918124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the in vitro activities of BB-K8 and three other aminoglycosides against 215 strains of Pseudomonas and Enterobacteriaceae with variable sensitivity to kanamycin and gentamicin.
    Yourassowsky E; Schoutens E; Vanderlinden MP
    Chemotherapy; 1975; 21(1):45-51. PubMed ID: 807457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
    Sutherland CA; Verastegui JE; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
    McGrath BJ; Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1931-7. PubMed ID: 8239608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin.
    Van der Auwera P; Klastersky J
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1061-8. PubMed ID: 3116918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli.
    Fantin B; Ebert S; Leggett J; Vogelman B; Craig WA
    J Antimicrob Chemother; 1991 Jun; 27(6):829-36. PubMed ID: 1938689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa.
    Van Laethem Y; Husson M; Klastersky J
    Antimicrob Agents Chemother; 1984 Aug; 26(2):224-7. PubMed ID: 6435515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models.
    Leggett JE; Ebert S; Fantin B; Craig WA
    Scand J Infect Dis Suppl; 1990; 74():179-84. PubMed ID: 2151487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The postantibiotic effect of amikacin alone and in combination with piperacillin on gram-negative bacteria.
    Isaksson B; Hanberger H; Maller R; Nilsson LE; Nilsson M
    Scand J Infect Dis Suppl; 1990; 74():129-32. PubMed ID: 2129064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to gentamicin and amikacin of gram-negative organisms isolated from horses.
    Orsini JA; Benson CE; Spencer PA; Van Miller E
    Am J Vet Res; 1989 Jun; 50(6):923-5. PubMed ID: 2669575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].
    Schassan HH
    Infection; 1976; 4(2):35-41. PubMed ID: 789246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.